| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
GLP-1(7-37) acetate targets the glucagon receptor (GLP-1 receptor), a G-protein-coupled receptor expressed on pancreatic beta cells. Activation of the GLP-1 receptor stimulates glucose-dependent insulin secretion, enhances insulin biosynthesis, and promotes beta-cell survival. The compound is a full agonist at the GLP-1 receptor.
|
|---|---|
| ln Vitro |
In vitro, GLP-1(7-37) acetate augments glucose-induced insulin secretion in pancreatic beta cells. It acts as an intestinal insulinotropic hormone. The compound stimulates insulin secretion in a glucose-dependent manner. Detailed EC₅0 values are not extensively documented in the available literature.
|
| ln Vivo |
During the second hour of a 2-hour 11 mM hyperglycemic clamp, infusion of GLP-1(7-37) (0.5, 5, or 50 pmol/min/kg) resulted in a dose-related rise in glucose-stimulated plasma insulin. Rats had improved concentration and a higher rate of glucose infusion [2]. GLP-1(7-37) (5 pmol/min/kg) was infused into rats kept at 11 mM glucose for 1 to 7 hours, increasing plasma insulin concentrations in comparison to rats given a vehicle injection. kept growing. 2].
In vivo, GLP-1(7-37) acetate (0.5, 5, or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of glucose-stimulated plasma insulin concentration and an increased glucose infusion rate in rats. Continuous infusion of GLP-1(7-37) (5 pmol/min/kg) from hour 1 to hour 7 has also been studied. |
| Enzyme Assay |
The in vitro receptor binding assay for GLP-1 uses membrane preparations from cells expressing the GLP-1 receptor. Competitive binding is performed using radiolabeled GLP-1 or GLP-1 analogs in the presence of varying concentrations of GLP-1(7-37) acetate. Functional assays measure cAMP accumulation in response to receptor activation. EC₅0 values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, pancreatic beta-cell lines (such as INS-1 or MIN6 cells) or primary islet cells are cultured and treated with GLP-1(7-37) acetate at various concentrations. Insulin secretion is measured by ELISA or radioimmunoassay. cAMP accumulation is measured by ELISA. Cells are maintained under standard culture conditions and experiments are typically performed in triplicate with appropriate glucose concentrations.
|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rats, weighing 300 to 350 g, were administered intravenous (iv) (iv)glucose at a variable rate for 7 hrs (hrs (hours)) to maintain plasma glucose concentration at 11 mM [2].
Doses: 5 pmol/min/kg. Route of Administration: intravenous (iv) (iv)injection 1 hour to 7 hrs (hrs (hours)) [2]. Experimental Results: Plasma insulin concentrations were consistently increased compared to vehicle-injected rats. Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rats, weighing 300 to 350 g, with plasma glucose concentration maintained at 11 mM [2]. Doses: 0.5, 5 or 50 pmol/min/kg. Route of Administration: intravenously (iv) (iv)(iv) during the second hour of a 2-hour 11 mmol/L hyperglycemic clamp. Experimental Results: Produced dose-related potentiation of glucose-stimulated increases in plasma insulin concentrations and increases in glucose infusion rates. In vivo animal studies for GLP-1(7-37) acetate typically involve rat models using hyperglycemic clamp techniques. The peptide is infused intravenously at various doses (0.5, 5, or 50 pmol/min/kg). Plasma insulin concentrations and glucose infusion rates are measured. Glucose tolerance tests may also be performed. Efficacy is evaluated by enhancement of glucose-stimulated insulin secretion and glucose disposal. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of GLP-1(7-37) acetate indicate that it is administered via infusion due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). The compound has molecular formula C1₅3H232N40O4₉ and molecular weight 3415.72. Purity is typically ≥98%. The peptide is soluble in aqueous buffers and DMSO. Storage at -20degC is recommended.
|
| Toxicity/Toxicokinetics |
Toxicological data for GLP-1(7-37) acetate are not well characterized in the public domain. As a research peptide, standard safety precautions should be observed. The compound is for laboratory use only and not intended for human therapeutic applications. GLP-1 receptor agonists as a class are generally well-tolerated but may have gastrointestinal side effects. Comprehensive toxicity profiling would be required for therapeutic development.
|
| References |
[1]. Sarrauste de Menthiere, C. et al. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production. European journal of medicinal chemistry 39, 473-480, doi:10.1016/j.ejmech.2004.02.002 (2004).
[2]. Hargrove DM, et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism. 1995 Sep;44(9):1231-7. |
| Additional Infomation |
GLP-1(7-37) acetate (CAS# 1450806-98-0) is an intestinal insulinotropic hormone that augments glucose-induced insulin secretion. It targets the GLP-1 receptor and is used in diabetes and metabolic research. The peptide has molecular formula C1₅3H232N40O4₉ and molecular weight 3415.72. It is not approved for clinical use.
|
| Molecular Formula |
C153H232N40O49
|
|---|---|
| CAS # |
1450806-98-0
|
| Related CAS # |
GLP-1(7-37);106612-94-6
|
| PubChem CID |
16133830
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
50
|
| Hydrogen Bond Acceptor Count |
52
|
| Rotatable Bond Count |
111
|
| Heavy Atom Count |
238
|
| Complexity |
7820
|
| Defined Atom Stereocenter Count |
30
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~14.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 12.5 mg/mL (3.66 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
